Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 9/20 | 0.40 |
| ▸ | JUN | P05412 | 6/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.40 |
| ▸ | RELA | Q04206 | 6/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | XPO1 | O14980 | 4/20 | 0.36 |
| ▸ | ATF1 | P18846 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4765257 | 0.87 | STK17B (0.47) | NFKB1JUNNFKB2RELASTK17B | |
| SCHEMBL4772853 | 0.85 | TRPA1 (0.41) | NFKB1JUNNFKB2RELASTK17B | |
| SCHEMBL4768083 | 0.85 | STK17B (0.40) | NFKB1JUNNFKB2RELASTK17B | |
| SCHEMBL4773876 | 0.85 | NFKB1 (0.40) | NFKB1JUNNFKB2RELASTK17B | |
| SCHEMBL4772216 | 0.85 | STK17B (0.40) | NFKB1JUNNFKB2RELASTK17B | |
| SCHEMBL4765932 | 0.85 | STK17B (0.43) | NFKB1JUNNFKB2RELASTK17B | |
| SCHEMBL4768852 | 0.84 | ALDH1A1 (0.46) | NFKB1JUNNFKB2RELASTK17B | |
| SCHEMBL4768060 | 0.84 | LRRK2 (0.46) | NFKB1JUNNFKB2RELASTK17B | |
| SCHEMBL4769049 | 0.84 | L3MBTL1 (0.48) | NFKB1STK17BSTK17AATF1ALDH1A1 | |
| SCHEMBL4770559 | 0.83 | JAK2 (0.43) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303496-B9 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1303496-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| US-6908920-B2 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-06-21 | — | — | US | disclosed |
| US-20030216406-A1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| EP-1303496-A1 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002004429-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216406-A1 | Pyrimidine derivatives | TYMP, TYMS, CCNT1 | NFKB1 2034/4885JUN 2823/4885NFKB2 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.